Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|7|3|166-174

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.7, Iss.3, 2012-08, pp. : 166-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Direct Factor IIa and Xa Inhibitors: Mechanisms of Action and Preclinical Studies

By  

Current Clinical Pharmacology, Vol. 7, Iss. 3, 2012-01 ,pp. : 149-165

Bentham Science Publishers

Access to resources Recommend Favorite

Dronedarone: A New Hope for Stroke Prevention in Atrial Fibrillation?

By Shantsila Alena   Lip Gregory Y.H.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 355-356

Adis International

Access to resources Recommend Favorite

Stroke Prevention in Atrial Fibrillation: Putting the Guidelines into Practice

By Mant Jonathan   Edwards Duncan  

Drugs & Aging, Vol. 27, Iss. 11, 2010-11 ,pp. : 859-870

Adis International

Access to resources Recommend Favorite

Guidelines for Stroke Prevention in Patients with Atrial Fibrillation

By Howard P.A.  

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 997-1009

Adis International

Access to resources Recommend Favorite

Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 35, Iss. 4, 2005-12 ,pp. : 279-283

John Wiley & Sons Inc

Access to resources Recommend Favorite